Liposuction on a GLP-1: the disclosure that changes your anesthesia plan

There is a conversation happening in surgical centers right now that has not made it into patient-facing material, and the gap is costing people cancelled operations on the morning of surgery. A large share of body contouring patients arriving for consultations have lost significant weight on semaglutide, tirzepatide, or a related medication. That weight loss is genuinely good news for the result. It also introduces a specific anesthesia consideration that has nothing to do with the surgery itself and everything to do with the stomach.

The original element in this piece is a disclosure protocol. Below is exactly what to volunteer, at which of the three pre-operative touchpoints, followed by a stop-or-continue decision map and four questions that will tell you within a minute whether the team operating on you has an actual plan or is improvising. This is assembled from published anesthesia society guidance and from the gastric ultrasound literature, and the reasoning behind each step is stated so you can see what is established and what is still being worked out.

The mechanism, briefly. GLP-1 receptor agonists work partly by slowing gastric emptying. That is not a side effect, it is a substantial part of how they produce fullness and reduce intake. Under general anesthesia or deep sedation, the protective reflexes that keep stomach contents out of the airway are suppressed. Anesthesia fasting rules exist because an empty stomach makes that suppression safe. A medication that deliberately slows emptying can leave solid or liquid content in the stomach after a fasting period that would ordinarily be more than sufficient.

This is not theoretical. Prospective work using gastric ultrasound has examined the relationship between residual gastric content and perioperative semaglutide use and found retained content in patients who had fasted appropriately (Anaesthesia, 2024). Further cross-sectional work has looked specifically at what happens after holding the medication before elective surgery, which is the exact scenario most patients will be in (BMC Anesthesiol, 2026). The American Society of Anesthesiologists issued guidance to clinicians on holding these medications before elective procedures, which is publicly available and worth reading in the original (ASA, 2023). The FDA maintains a page on medications containing semaglutide for anyone who wants the regulatory-side information (FDA).

Why patients do not mention it. Three reasons, all understandable. It is prescribed by a different doctor, often through a telehealth service, so it does not feel like it belongs on a surgical intake form. It is a weekly injection rather than a daily pill, so it does not register as a current medication in the way a daily tablet does. And there is a privacy instinct around weight loss medication that makes people quietly omit it. Every one of those omissions creates the same problem: an anesthesiologist who finds out at the pre-operative interview, on the morning of surgery, with no time to adjust.

The disclosure protocol. There are three moments where this needs to be said, and saying it at only one of them is not enough, because the three people involved often do not share notes as fully as patients assume.

Touchpoint one, the surgical consultation. Say it in the first conversation about candidacy, not in the paperwork. The exact phrasing that works: name the drug, name the dose, name the day of the week you inject, name the date you started, and name whether the dose has changed recently. Recent dose escalation matters more than long stable use, because gastrointestinal effects are typically strongest after an increase. If you have been on a stable dose for a year with no nausea, say that too, because it is relevant in the other direction.

Touchpoint two, the pre-operative assessment. This is where the actual decision gets made and where the anesthesia team, rather than the surgeon, needs the information. Ask directly whether the anesthesiologist has been informed. Do not assume the referral letter carried it. This is also the appointment where you should raise it alongside everything else that affects your anesthesia plan, because the type of anesthesia proposed for your case changes how much this matters.

Touchpoint three, the prescribing clinician. Before you stop or hold anything, tell whoever prescribes it. This is not optional and it is the step people skip. If the medication is being taken for type 2 diabetes rather than for weight loss, holding it has metabolic consequences that need managing, and the decision belongs to the prescriber and the anesthesiologist together, not to you and not to the surgeon alone.

The stop-or-continue map. The honest framing is that guidance in this area has been evolving quickly, and different institutions land in different places. What is consistent is the structure of the decision.

If it is a weekly injection, the typical approach involves holding it for a period measured in weeks rather than days before an elective procedure. If it is a daily formulation, the hold period is shorter. If it is prescribed for diabetes, the hold requires a parallel plan for glucose control and the prescriber has to be involved. If holding is not appropriate or was not done, the plan shifts rather than disappearing: options include treating the stomach as full and adjusting airway management accordingly, using gastric ultrasound to assess actual content, extending the clear-liquid-only period, or moving the case. And if you have ongoing nausea, vomiting, or a sensation of food sitting undigested, that is not a detail to mention in passing. It is the most predictive symptom in this entire conversation and it should be volunteered unprompted.

Note what is not on that list: deciding yourself. Stopping a prescribed medication without telling the prescriber is its own risk, and it is a common enough impulse among patients who read something like this article that it deserves saying plainly.

Four questions that reveal whether there is a plan. Ask these at the pre-operative assessment and listen to whether the answers are specific. First, has the anesthesiologist been told which GLP-1 medication I am on and when my last dose was. Second, what is this facility's hold protocol for my specific drug and dosing interval. Third, if I have retained gastric content on the day, what happens: is the case delayed, is the airway plan changed, or is gastric ultrasound available here. Fourth, who is coordinating this with my prescriber. Vague answers to all four are informative in themselves.

Where the contouring conversation comes back in. The reason any of this matters is that GLP-1 weight loss changes what liposuction is being asked to do. Substantial weight loss shifts the problem from volume toward skin quality, and the patients who are happiest with their results are typically the ones who understood before surgery that skin retraction has limits and that liposuction removes fat rather than tightening the skin envelope. Whether you are a strong candidate at your current weight is worth revisiting honestly against the standard candidacy criteria, because the answer can change substantially after a large loss.

What the studies do not tell you. The gap here is specific and worth naming. Almost all of the published gastric emptying research in this area comes from general surgical and endoscopy populations, not from elective cosmetic surgery under sedation or tumescent local anesthesia, which is how a large share of liposuction is actually performed. Nobody has published a study asking what the residual gastric content risk looks like in a healthy outpatient having tumescent liposuction with light sedation. It is plausibly lower than in a general anesthetic case. It is also unstudied. Meanwhile the optimal hold duration is still being refined, which is why guidance has shifted more than once. Anyone who tells you the numbers are settled is ahead of the evidence.

The practical bottom line. This is a disclosure problem, not a disqualification. GLP-1 use does not prevent you from having liposuction. Undisclosed GLP-1 use is what causes a morning-of cancellation or, far more rarely and far more seriously, an airway event. The rest of your pre-operative preparation is built on the same principle, and the realistic limits of the procedure are worth understanding alongside it.

One sentence to carry into the consultation: the weekly injection you do not think of as a medication is the single most useful thing you can tell your anesthesiologist this year.